Bachem, the world market leader in peptides, has automated and digitalised one of its core business processes, solid-phase peptide synthesis (SPPS). The company describes this as the start of its journey to Industry 4.0. The process is described in detail on the company website (www.bachem.com/news/bachem-journey-to-industry-4-0/).
Bachem has entered a strategic collaboration under which it will provide the infrastructure and expertise to implement Eli Lilly & Company’s novel manufacturing technology for oligonucleotide APIs. It will also supply R&D and production at its site in Bubendorf, Switzerland, to make GMP-grade material using this technology.
Bachem, the world’s largest peptides manufacturer, has announced some results of two studies it carried out with Novo Nordisk, seeking to make solid-phase peptide synthesis (SPPS) greener.
SPPS requires large volumes of solvents and the current gold standards, because of their excellent solubilisation and stability properties for reagents and resin swelling capabilities, are N-dimethylformamide (DMF), dichloromethane and N-methyl-2-pyrrolidone. All now face restrictions under REACH because of their hazardous nature.
Bachem, the world’s largest producer of pharmaceutical peptides and ologonucleotides, has signed an exclusive licensing agreement with Japanese firm Jitsubo related to the latter’s liquid-phase peptide technology. Molecular Hiving. Financial terms were not disclosed. The two firms have already worked together on APIs and cosmetic peptides.